These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. pH-sensitive polymer-modified liposome-based immunity-inducing system: Effects of inclusion of cationic lipid and CpG-DNA. Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K Biomaterials; 2017 Oct; 141():272-283. PubMed ID: 28704679 [TBL] [Abstract][Full Text] [Related]
5. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Yuba E; Harada A; Sakanishi Y; Watarai S; Kono K Biomaterials; 2013 Apr; 34(12):3042-52. PubMed ID: 23374704 [TBL] [Abstract][Full Text] [Related]
6. The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy. Yuba E; Kono Y; Harada A; Yokoyama S; Arai M; Kubo K; Kono K Biomaterials; 2013 Jul; 34(22):5711-21. PubMed ID: 23639528 [TBL] [Abstract][Full Text] [Related]
7. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. Hattori Y; Kawakami S; Lu Y; Nakamura K; Yamashita F; Hashida M J Gene Med; 2006 Jul; 8(7):824-34. PubMed ID: 16625665 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine. Okazaki S; Iwasaki T; Yuba E; Watarai S J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431 [TBL] [Abstract][Full Text] [Related]
9. Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines. Watarai S; Iwase T; Tajima T; Yuba E; Kono K; Sekiya Y Vet Immunol Immunopathol; 2014 Mar; 158(1-2):62-72. PubMed ID: 23790647 [TBL] [Abstract][Full Text] [Related]
10. Gene delivery to dendritic cells mediated by complexes of lipoplexes and pH-sensitive fusogenic polymer-modified liposomes. Yuba E; Kojima C; Sakaguchi N; Harada A; Koiwai K; Kono K J Control Release; 2008 Aug; 130(1):77-83. PubMed ID: 18573563 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages. Yasuda S; Yoshida H; Nishikawa M; Takakura Y Mol Pharm; 2010 Apr; 7(2):533-42. PubMed ID: 20047296 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Hattori Y; Kawakami S; Suzuki S; Yamashita F; Hashida M Biochem Biophys Res Commun; 2004 May; 317(4):992-9. PubMed ID: 15094367 [TBL] [Abstract][Full Text] [Related]
13. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100 [TBL] [Abstract][Full Text] [Related]
14. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727 [TBL] [Abstract][Full Text] [Related]
15. pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Yuba E; Kojima C; Harada A; Tana ; Watarai S; Kono K Biomaterials; 2010 Feb; 31(5):943-51. PubMed ID: 19850335 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Sakurai F; Terada T; Maruyama M; Watanabe Y; Yamashita F; Takakura Y; Hashida M Cancer Gene Ther; 2003 Sep; 10(9):661-8. PubMed ID: 12944985 [TBL] [Abstract][Full Text] [Related]
17. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Mandal M; Lee KD Biochim Biophys Acta; 2002 Jun; 1563(1-2):7-17. PubMed ID: 12007619 [TBL] [Abstract][Full Text] [Related]
18. Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects. Miura N; Akita H; Tateshita N; Nakamura T; Harashima H Mol Ther; 2017 Apr; 25(4):1003-1013. PubMed ID: 28236573 [TBL] [Abstract][Full Text] [Related]
19. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752 [TBL] [Abstract][Full Text] [Related]
20. Bioactive polysaccharide-based pH-sensitive polymers for cytoplasmic delivery of antigen and activation of antigen-specific immunity. Yuba E; Yamaguchi A; Yoshizaki Y; Harada A; Kono K Biomaterials; 2017 Mar; 120():32-45. PubMed ID: 28027502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]